HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Interest Income

Income earned on cash, deposits, and investments held by the company.

HUTCHMED (China) LimitedNASDAQ: HCM

Interest Income · Q2 FY2025 · quarter ended Jun 2025

Interest income remains negative

Q2 FY2025 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $37.21M. Over 3 fiscal years it compounded at +73.4% a year.

Context

  • Interest income amounted to 9.1% of revenue in FY2025, up 2.7 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $9.3M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
$0— QoQ
Last fiscal yearDec 2025
$50.01M+24.8% YoY
LTMJun 2025
$37.21M+3.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+24.8%——
3-year CAGR+73.4%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
50.01M USD
Year-over-year change
+24.8%
4-year CAGR
+121.5%

Interest Income vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.6% is the 4th highest of 8, against a peer median of -16.1%.
  • Interest income amounts to 6.2% of revenue for HCM, versus a peer median of 10.3%.
HCM Competitors
Interest Income for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€420.15M EUR—+74.6%15.9%
GMABGenmab A/SLTM Jun 2026$129.91M USD—-24.7%3.1%
INCYIncyte CorporationLTM Jun 2026$129.34M USD+86.7%—2.2%
AAPGAscentage Pharma Group InternationalFY2025CN¥79.89M CNY+111.1%+101.8%14.3%
EXELExelixis, Inc.LTM Jul 2026$63.69M USD-16.1%+27.9%2.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026$58M USD+23.4%+36.8%49.6%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$43.41M USD-18.5%+128.0%19.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$37.21M USD+3.6%+73.4%6.2%
ZLABZai Lab LimitedLTM Jun 2026$27.93M USD-21.5%+31.4%6.2%
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M USD-48.6%+69.9%1.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.49M USD—-87.8%23.0%
Peer median (excluding HCM) —-16.1%+36.8%10.3%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.